Arbutus Biopharma Corporation posted an updated corporate presentation on November 12, 2026.
ABUS · Arbutus Biopharma Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 54%
- Last earnings
- Nov 21, 2024
- Latest filing
- 10-Q · Nov 10
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Arbutus Biopharma Corporation said the FDA lifted its clinical hold on AB-101’s IND application in October 2026, allowing additional clinical development in the United States.
Arbutus Biopharma reported net income of $59.1 million for the quarter ended September 30, 2026, compared with a net loss of $7.7 million a year earlier. It completed a tender offer in early October 2026, buying 46 million shares at $5.00 per share and returning $230 million to shareholders. Cash, cash equivalents and marketable securities were $337.5 million as of September 30, 2026.
The FDA notified the company that the clinical hold on the IND application for AB-101, its oral PD-L1 inhibitor, has been removed, allowing additional clinical development in the United States. Arbutus is evaluating next steps for AB-101's continued development.
Arbutus Biopharma Corporation accepted 46,000,000 Shares at US$5.00 per Share, an aggregate US$230 million purchase price representing approximately 23 percent of its outstanding Shares; settlement is expected on or about October 5, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| cash, cash equivalents and marketable securities | $337.5M | As of September 30, 2026 | — |
| common shares issued and outstanding | 199.3M | As of September 30, 2026 | — |
| Options granted during period | 13,400 | the three months ended September 30, 2026 filing | — |
| stock options and unvested restricted stock units outstanding | 6.4M | As of September 30, 2026 | — |
| Weighted average exercise price | $4.41 | the three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABUS
this stock
Arbutus Biopharma Corp
|
$616.24M | -16.4% | +128.2% | 3.6 | 13.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABUS | -1.7% | -4.3% | -5.6% | -4.5% | -16.4% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +6.9% | +4.9% | +3.6% | +4.2% | -17.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.